Bliss GVS Pharma Ltd

NSE: BLISSGVS BSE: 506197

₹216.26

(-3.03%)

Fri, 13 Mar 2026, 08:03 am

MTF 5xInvest in Bliss GVS Pharma Ltd with 5x Leverage Buy with MTF

Market Cap23.56B

PE Ratio21.26

Dividend0.45

Health Technology

Pharmaceuticals: Major

24.5K

Bliss GVS Pharma EV/EBITDA Ratio

D/E EV EV/EBITDA P/B P/CF P/E P/S ROE %

Particulars	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Price to earnings ratio	12.67	4.89	8.23	2.72	8.89	5.74	4.56	4.77	11.21	22.20	15.85	22.19	34.27	15	10.69	15.20	53.82	10.61	15.84	14.79
Price to book ratio	3.37	1.37	4.58	1.05	2.78	1.40	1.14	1.07	1.60	3.95	3.17	3.74	3.76	2.87	1.41	1.26	0.97	0.84	1.22	1.18
Price to sales ratio	2.66	0.30	2.71	0.77	2.19	1.07	0.90	0.70	1.35	3.30	2.44	4.82	5.54	2.09	1.52	1.83	1.10	1.01	1.56	1.55
Price to cash flow ratio	52.24	0	0	6.35	66.95	10.55	6.90	0	6.47	35	12.43	8.06	23.16	21.23	20.81	16.52	5.85	18.22	11.75	10.79
Enterprise value	150.01M	222.68M	2.84B	974.75M	3.63B	2.23B	2.26B	4B	5.61B	14.56B	14B	19.61B	20.56B	18.65B	10.77B	10.38B	7.69B	7.79B	11.14B	11.63B
Enterprise value to EBITDA ratio	8.27	2.37	7.41	2.49	7	3.79	3.27	3.78	8.47	14.65	9.61	25.06	22.76	12.40	9.10	10.35	6.85	6.68	7.45	9.46
Debt to equity ratio	0.11	0.32	0.20	0.02	0.06	0.05	0.21	0.62	0.60	0.50	0.33	0.46	0.22	0.16	0.17	0.15	0.13	0.12	0.10	0.08
Return on equity %	29.24	27.47	79	46.99	36.17	27.10	27.85	24.63	15.05	19.20	22	11.31	5.84	20.93	14.08	8.87	1.85	8.32	8.15	8.36

Bliss GVS Pharma Ltd Enterprise Value to EBITDA Ratio

The Bliss GVS Pharma Ltd Enterprise Value to EBITDA Ratio is a key financial metric used by investors to evaluate Bliss GVS Pharma Ltd's valuation, profitability, and overall financial performance. Tracking the Bliss GVS Pharma Ltd Enterprise Value to EBITDA Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.

Bliss GVS Pharma Ltd (NSE: BLISSGVS, BSE: 506197) is currently trading at ₹216.26, with a market capitalization of ₹23.56B. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Bliss GVS Pharma Ltd Enterprise Value to EBITDA Ratio is essential for fundamental analysis.

Bliss GVS Pharma Ltd Enterprise Value to EBITDA Ratio Current Value

The current Bliss GVS Pharma Ltd Enterprise Value to EBITDA Ratio stands at 9.46.

The latest Bliss GVS Pharma Ltd Enterprise Value to EBITDA Ratio has increased compared to the previous period, indicating rising valuation or improved investor sentiment.

Bliss GVS Pharma Ltd Enterprise Value to EBITDA Ratio Historical Trend

The Bliss GVS Pharma Ltd Enterprise Value to EBITDA Ratio has shown the following historical trend:

2024: 9.46
2023: 7.45
2022: 6.68
2021: 6.85
2020: 10.35

The recent rise in Bliss GVS Pharma Ltd Enterprise Value to EBITDA Ratio suggests strengthening valuation trends and improving market sentiment.

What Bliss GVS Pharma Ltd Enterprise Value to EBITDA Ratio Indicates for Investors

The Bliss GVS Pharma Ltd Enterprise Value to EBITDA Ratio plays a crucial role in understanding the company's financial health and valuation.

This ratio is an important metric used in fundamental analysis of Bliss GVS Pharma Ltd.

Bliss GVS Pharma Ltd Enterprise Value to EBITDA Ratio Analysis Summary

The Bliss GVS Pharma Ltd Enterprise Value to EBITDA Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Bliss GVS Pharma Ltd Enterprise Value to EBITDA Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.

Regular tracking of Bliss GVS Pharma Ltd Enterprise Value to EBITDA Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800